Placebo News and Research

RSS

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).

9 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Peramivir drug safe, effective at alleviating influenza symptoms

An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.

6 Sep 2014

Current issue provides critical review of data concerned with antidepressant drugs

A paper in the current issue of Psychotherapy and Psychosomatics by Giovanni Fava, MD (University of Bologna) provides a critical review of the data concerned with antidepressant drugs.

4 Sep 2014

White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

A little white pill may help scientists learn why patients with cystic fibrosis have less exercise capacity than their peers, even if their lungs are relatively healthy.

3 Sep 2014

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix.

2 Sep 2014

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

2 Sep 2014

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.

2 Sep 2014

Ambulance administration of antiplatelet medication may help heart attack patients

Ambulance administration of the antiplatelet medication ticagrelor to patients with a type of heart attack known as ST segment elevation myocardial infarction (STEMI) is not better than hospital administration, in terms of improving blood flow in blocked arteries before a revascularisation procedure, according to a new study presented at ESC Congress 2014 today.

2 Sep 2014

Experimental agent TRO40303 ineffective in patients with heart attack

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI) presented today as a Hot Line the ESC Congress 2014 with simultaneous publication in the European Heart Journal.

1 Sep 2014

Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014.

1 Sep 2014

Serelaxin reduces occurrence of in-hospital worsening heart failure

Serelaxin reduces the occurrence of in-hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX-AHF trial. The results were presented for the first time today at ESC Congress by co-principal investigator Professor John R. Teerlink.

1 Sep 2014

Darapladib drug fails to reduce risk of recurrent major coronary events

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) did not reduce the risk of recurrent major coronary events, according to a study published by JAMA.

1 Sep 2014

Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy reduces the risk of cardiovascular (CV) events, strokes and mortality in hypertensive older adults, according to research presented at ESC Congress 2014 today by Dr Maciej Ostrowski from Poland.

1 Sep 2014

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Heart failure patients with iron deficiency can experience significant and sustainable improvements in functional capacity and quality of life as well as reduced risk of hospital admission for worsening heart failure by receiving just one to two intravenous doses of an iron supplement, according to the results of a study presented today at ESC Congress 2014.

30 Aug 2014

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014.

30 Aug 2014

Plant-based medication after cardiac surgery shows mixed results in reducing complications

Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA.

30 Aug 2014

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s.

29 Aug 2014

New treatment fights respiratory syncytial virus

The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

29 Aug 2014

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.

28 Aug 2014

Placebo News and Research

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Peramivir drug safe, effective at alleviating influenza symptoms

Current issue provides critical review of data concerned with antidepressant drugs

White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

Ambulance administration of antiplatelet medication may help heart attack patients

Experimental agent TRO40303 ineffective in patients with heart attack

Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

Serelaxin reduces occurrence of in-hospital worsening heart failure

Darapladib drug fails to reduce risk of recurrent major coronary events

Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

Plant-based medication after cardiac surgery shows mixed results in reducing complications

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

New treatment fights respiratory syncytial virus

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News